Volume 10, Issue 11 pp. 857-865

Original Article

Interleukin-2 receptor antagonists: Protective factors against new-onset diabetes after renal transplantation

白细胞介素2受体拮抗剂:肾移植后新发糖尿病的保护因素

Mengjuan Xue,

Mengjuan Xue

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Elderly Endocrinology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China

These authors contributed equally to this work.Search for more papers by this author

Chenhe Zhao,

Chenhe Zhao

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

These authors contributed equally to this work.Search for more papers by this author

Chaoyang Lv,

Chaoyang Lv

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Endocrinology and Metabolism, The Seventh People’s Hospital of Zhengzhou, Zhengzhou, China

Search for more papers by this author

Minling Chen,

Minling Chen

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Endocrinology and Metabolism, People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine (The People’s Hospital of Fujian Province), Fuzhou, China

Search for more papers by this author

Ming Xu,

Ming Xu

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation, Shanghai, China

Search for more papers by this author

Ruiming Rong,

Ruiming Rong

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation, Shanghai, China

Search for more papers by this author

Yao Zhang,

Yao Zhang

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

Jing Liang,

Jing Liang

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

Jian Gao,

Jian Gao

Evidence Base Medicine Center, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

Mingxiang Yu,

Corresponding Author

Mingxiang Yu

[email protected]

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Correspondence

Mingxiang Yu, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.

Tel: +86 13918283426

Fax: +86 21 5496 0129

Email: [email protected]

Search for more papers by this author

Tongyu Zhu,

Tongyu Zhu

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation, Shanghai, China

Search for more papers by this author

Xin Gao,

Xin Gao

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

Mengjuan Xue,

Mengjuan Xue

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Elderly Endocrinology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China

These authors contributed equally to this work.Search for more papers by this author

Chenhe Zhao,

Chenhe Zhao

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

These authors contributed equally to this work.Search for more papers by this author

Chaoyang Lv,

Chaoyang Lv

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Endocrinology and Metabolism, The Seventh People’s Hospital of Zhengzhou, Zhengzhou, China

Search for more papers by this author

Minling Chen,

Minling Chen

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Endocrinology and Metabolism, People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine (The People’s Hospital of Fujian Province), Fuzhou, China

Search for more papers by this author

Ming Xu,

Ming Xu

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation, Shanghai, China

Search for more papers by this author

Ruiming Rong,

Ruiming Rong

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation, Shanghai, China

Search for more papers by this author

Yao Zhang,

Yao Zhang

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Department of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

Jing Liang,

Jing Liang

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

Jian Gao,

Jian Gao

Evidence Base Medicine Center, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

Mingxiang Yu,

Corresponding Author

Mingxiang Yu

[email protected]

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Correspondence

Mingxiang Yu, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.

Tel: +86 13918283426

Fax: +86 21 5496 0129

Email: [email protected]

Search for more papers by this author

Tongyu Zhu,

Tongyu Zhu

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation, Shanghai, China

Search for more papers by this author

Xin Gao,

Xin Gao

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China

Search for more papers by this author

First published: 25 March 2018

https://doi.org/10.1111/1753-0407.12663

Citations: 3

Share a link

Email
Wechat
Bluesky

Abstract

Background

The aim of the present study was to examine the association between interleukin-2 receptor antagonists (IL-2Ra) and new-onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs).

Methods

Between January 1993 and March 2014, 915 patients underwent renal transplantation at Zhongshan Hospital. In all, 557 RTRs were included in the present retrospective cohort study. The incidence of NODAT in this cohort was determined and multivariate Cox regression analysis was used to evaluate the risk factors for NODAT and to show the association between IL-2Ra use and NODAT development among RTRs. The cumulative incidence of NODAT was compared between groups treated with or without IL-2Ra.

Results

The mean ±SD postoperative follow-up was 5.08 ±3.17 years. The incidence of NODAT at the end of follow-up was 20.3%. After adjusting for potential confounders in the multivariate logistic regression (i.e. age, sex, body mass index, history of smoking, family history of diabetes, duration of dialysis, type of dialysis, donor type, recovery of graft function, acute rejection, hepatitis B or C or cytomegalovirus infection, fasting plasma glucose levels before and 1 week after transplantation, preoperative total cholesterol and triglyceride levels, daily dose of glucocorticoid, immunosuppressive regimen type, and immunosuppressant concentration after transplantation), IL-2Ra use was found to be related to a reduced incidence of NODAT.

Conclusions

Use of IL-2Ra is associated with protection against the development of NODAT in RTRs.

Abstract

摘要

背景

本研究旨在探讨白细胞介素2受体拮抗剂(IL-2Ra)与肾移植患者移植后新发糖尿病(new-onset diabetes after transplantation,NODAT)的关系。

方法

1993年1月至2014年3月在复旦大学附属中山医院接受肾移植的患者共915例, 最终557例患者纳入此项回顾性队列研究。计算肾移植患者NODAT的发病率, 采用多元COX回归分析评估NODAT的危险因素及探讨IL-2Ra与NODAT的关系。同时比较IL-2Ra治疗组与非IL-2Ra组NODAT的累积发病率。

结果

术后平均随访时间为5.08 ± 3.17年, 随访结束时NODAT的发病率为20.3%。多元回归分析校正了可能影响NODAT发生的因素(包括年龄、性别、体重指数、吸烟史、糖尿病家族史、透析持续时间、透析类型、供肾类型、肾功能恢复情况、急性排斥反应、乙肝感染、丙肝感染、巨细胞病毒感染、术前和术后1周空腹血糖水平、术前总胆固醇和甘油三脂水平、糖皮质激素日剂量、免疫抑制剂类型及术后免疫抑制剂的浓度),结果显示IL-2Ra可降低NODAT的发生率。

结论

IL-2Ra为肾移植患者发生NODAT的保护因素

References

1Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant. 2011; 11: 450–462.
10.1111/j.1600-6143.2010.03283.x
CAS PubMed Web of Science® Google Scholar
2Moore R, Ravindran V, Baboolal K. The burden of new-onset diabetes mellitus after transplantation. Clin Transplant. 2006; 20: 755–761.
10.1111/j.1399-0012.2006.00565.x
CAS PubMed Web of Science® Google Scholar
3Prasad GV, Huang M, Silver SA et al. Metabolic syndrome definitions and components in predicting major adverse cardiovascular events after kidney transplantation. Transpl Int. 2015; 28: 79–88.
10.1111/tri.12450
PubMed Web of Science® Google Scholar
4Prasad N, Gurjer D, Bhadauria D et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? Nephrology (Carlton). 2014; 19: 244–250.
10.1111/nep.12209
CAS PubMed Web of Science® Google Scholar
5Bayes B, Pastor MC, Lauzurica R, Granada ML, Salinas I, Romero R. Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus? Transplant Proc. 2007; 39: 2248–2250.
10.1016/j.transproceed.2007.06.021
CAS PubMed Web of Science® Google Scholar
6Boillot O, Mayer DA, Boudjema K et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study. Liver Transpl. 2005; 11: 61–67.
10.1002/lt.20307
CAS PubMed Web of Science® Google Scholar
7Vitko S, Klinger M, Salmela K et al. Two corticosteroid-free regimens – tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil – in comparison with a standard triple regimen in renal transplantation: Results of the Atlas study. Transplantation. 2005; 80: 1734–1741.
10.1097/01.tp.0000188300.26762.74
CAS PubMed Web of Science® Google Scholar
8Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003; 75 (Suppl. 10): S3–S24.
PubMed Google Scholar
9 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 (Suppl. 1): S81–S90.
10.2337/dc14-S081
PubMed Web of Science® Google Scholar
10Wyzgal J, Paczek L, Sanko-Resmer J et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. Ann Transplant. 2007; 12: 26–29.
CAS PubMed Web of Science® Google Scholar
11Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998; 338: 161–165.
10.1056/NEJM199801153380304
CAS PubMed Web of Science® Google Scholar
12Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997; 350: 1193–1198.
10.1016/S0140-6736(97)09278-7
CAS PubMed Web of Science® Google Scholar
13Xue M, Lv C, Chen X et al. Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study. J Diabetes. 2016; 8: 579–587.
10.1111/1753-0407.12356
CAS PubMed Web of Science® Google Scholar
14ter Meulen CG, van Riemsdijk I, Hene RJ et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: A prospective, randomized, multicenter study. Am J Transplant. 2004; 4: 803–810.
10.1111/j.1600-6143.2004.00419.x
CAS PubMed Web of Science® Google Scholar
15Hahn HJ, Lucke S, Kloting I, Volk HD, Baehr RV, Diamantstein T. Curing BB rats of freshly manifested diabetes by short-term treatment with a combination of a monoclonal anti-interleukin 2 receptor antibody and a subtherapeutic dose of cyclosporin A. Eur J Immunol. 1987; 17: 1075–1078.
10.1002/eji.1830170728
CAS PubMed Web of Science® Google Scholar
16Ugrasbul F, Moore WV, Tong PY, Kover KL. Prevention of diabetes: Effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat. Pediatr Diabetes. 2008; 9: 596–601.
10.1111/j.1399-5448.2008.00417.x
CAS PubMed Web of Science® Google Scholar
17Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation. 2013; 96: 726–731.
10.1097/TP.0b013e3182a012f3
CAS PubMed Web of Science® Google Scholar
18Cosio FG, Kudva Y, van der Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005; 67: 2415–2421.
10.1111/j.1523-1755.2005.00349.x
PubMed Web of Science® Google Scholar
19Oruc M, Koseoglu K, Seyahi N, Alagoz S, Trabulus S, Altiparmak MR. Progression of metabolic syndrome in renal transplant recipients. Transplant Proc. 2013; 45: 3273–3278.
10.1016/j.transproceed.2013.06.005
CAS PubMed Web of Science® Google Scholar
20Chen HF, Chen P, Li CY. Risk of malignant neoplasm of the pancreas in relation to diabetes: A population-based study in Taiwan. Diabetes Care. 2011; 34: 1177–1179.
10.2337/dc10-2006
PubMed Web of Science® Google Scholar
21Choi JY, Kwon OJ. Post-transplant diabetes mellitus: Is it associated with poor allograft outcomes in renal transplants? Transplant Proc. 2013; 45 (8): 2892–2898.
10.1016/j.transproceed.2013.08.067
CAS PubMed Web of Science® Google Scholar
22Sezer S, Akgul A, Altunoglu A, Arat Z, Ozdemir FN, Haberal M. Posttransplant diabetes mellitus: Impact of good blood glucose regulation on renal transplant recipient outcome. Transplant Proc. 2006; 38: 533–536.
10.1016/j.transproceed.2005.12.106
CAS PubMed Web of Science® Google Scholar
23Miles AM, Sumrani N, Horowitz R et al. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation. 1998; 65: 380–384.
10.1097/00007890-199802150-00014
CAS PubMed Web of Science® Google Scholar
24Tufton N, Ahmad S, Rolfe C, Rajkariar R, Byrne C, Chowdhury TA. New-onset diabetes after renal transplantation. Diabet Med. 2014; 31: 1284–1292.
10.1111/dme.12534
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume10, Issue11

November 2018

Pages 857-865

This article also appears in:

Interleukin-2 receptor antagonists: Protective factors against new-onset diabetes after renal transplantation

白细胞介素2受体拮抗剂:肾移植后新发糖尿病的保护因素

Abstract

Background

Methods

Results

Conclusions

Abstract

摘要

背景

方法

结果

结论

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Interleukin-2 receptor antagonists: Protective factors against new-onset diabetes after renal transplantation

白细胞介素2受体拮抗剂:肾移植后新发糖尿病的保护因素

Abstract

Background

Methods

Results

Conclusions

Abstract

摘要

背景

方法

结果

结论

References

Citing Literature

References

Related

Information